Application of panaxadiol saponin component in preparing antischizophrenic drug

A technology of ginseng diol saponins and schizophrenia, applied in the field of medicine, can solve difficult problems such as medicinal value

Active Publication Date: 2014-12-24
ZHEJIANG UNIV
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This makes it difficult to realize the medicinal value of ginseng or American ginseng or their total saponins for effective treatment of central excitatory or inhibitory diseases and symptoms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of panaxadiol saponin component in preparing antischizophrenic drug
  • Application of panaxadiol saponin component in preparing antischizophrenic drug
  • Application of panaxadiol saponin component in preparing antischizophrenic drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] Example 1 Preparation of ginseng diol saponin components from ginseng rhizome medicinal materials

[0020] The ginseng diol saponin component of the present invention is prepared by the separation and purification method in Example 1 in Application No. 201210242928.1. Ginseng or American ginseng rhizomes or leaves are crushed into coarse powder, then extracted by percolation with 50% ethanol aqueous solution until the extract is colorless, combined percolation solution is decompressed to recover ethanol, and freeze-dried to obtain extract. The extract was dissolved in 45% ethanol aqueous solution, and the sample liquid was separated by macroporous adsorption resin column chromatography, first eluted with 45% ethanol aqueous solution until the eluent had no obvious saponin reaction, and then eluted with 70% ethanol aqueous solution to The eluate showed no obvious saponin reaction. The 70% ethanol eluate was decompressed to recover ethanol and freeze-dried to obtain to...

Embodiment 2

[0021] Example 2 Effect of Panaxadiol Saponin Components and Panaxatriol Saponin on the Neuromotor Toxicity of Haloperidol

[0022] 1. Panaxadiol saponins against neuromotor side effects caused by haloperidol

[0023] The reducing effect of panaxadiol saponins (Rb) on the neuromotor toxicity of haloperidol (HAL) was observed by pole climbing test.

[0024]Male ICR adult mice with a body weight of 30±5g after 6-7 days of acclimatization in the laboratory were randomly and evenly divided into haloperidol (2.0mg / kg, intraperitoneal injection ip) group, panaxadiol saponin (referred to as Rb, 40mg / kg, ip) combined with haloperidol (2.0mg / kg) (referred to as Rb40+HAL) group, panaxadiol saponin (referred to as Rb, 60mg / kg, ip) and haloperidol (2.0mg / kg ) combined (abbreviated as Rb60+HAL) group and ginseng diol saponin (abbreviated as Rb, 80mg / kg, ip) and haloperidol (2.0mg / kg) combined (abbreviated as Rb40+HAL) group, with 8 animals in each group. Rb intraperitoneal administra...

Embodiment 3

[0034] 1. The dose exploration of ginseng diol saponin components on the neuromotor attenuation effect caused by chlorpromazine

[0035] First explore the appropriate dose of chlorpromazine-induced neuromotor toxicity through the grip test of mice, and then use this dose to determine the influence of ginseng diol saponin components on the neuromotor toxicity caused by chlorpromazine.

[0036] Male ICR adult mice with a body weight of 30±5g after 6-7 days of acclimatization in the laboratory were randomly and evenly divided into three concentration gradient groups of chlorpromazine 4, 6, and 8 mg / kg (intraperitoneal injection, ip), In order to find a suitable dosage, there were 3 mice in each group. The device used to measure myasthenic toxicity in the grip test is the YLS-13A rat grip tester. Measuring conditions: Each mouse was measured 3 times in parallel with an interval of 5 minutes; data processing: reduction in gripping force (%) = [grasping strength before administra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of a panaxadiol saponin component in preparing an antischizophrenic drug. The application comprises treatment of schizophrenia and resistance of toxic side effect, namely an extrapyramidal symptom and the like which are caused by the antischizophrenic drug, wherein the antischizophrenic drug comprises the panaxadiol saponin component independently or with other medicines and other active compounds and pharmaceutically acceptable carriers. The invention proves that the panaxadiol saponin component (Rb) can improve the cognitive ability of a schizophrenia animal model, resist the nerve toxic side effect of multiple schizophrenia drugs, improve the negative symptoms (such as cognition impairment) of the schizophrenia and is applied to preparing the antischizophrenic drug.

Description

technical field [0001] The invention belongs to the field of medicine, and relates to the application of ginseng diol saponin active components (hereinafter referred to as Rb) in the preparation of drugs for preventing and treating mental diseases. More specifically, utilize the ginseng diol saponin component alone or together with other substances to comprise known anti-schizophrenia drugs particularly chlorpromazine, haloperidol, clozapine to make pharmaceutical preparations in the treatment of psychosis drugs The application of the ginseng diol saponin component is made of pharmaceutical preparations in combination with existing antipsychotics to play a synergistic and attenuating effect. Background technique [0002] Existing antipsychotic drugs have many defects, and safer and more effective therapeutic drugs are needed. [0003] With the acceleration of the pace of society, people face pressure from all aspects and are in a sub-health state for a long time. Over time,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P25/18A61P25/28A61K31/5415A61K31/551A61K31/4515
Inventor 连晓媛钱恒张治针周广骏
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap